

MEI SHENG DUH, M.P.H., Sc.D.
Managing Principal / Chief Epidemiologist

Phone: 617 425-8131
Fax: 617 425-8001
mei.duh@analysisgroup.com

111 Huntington Avenue
14th Floor
Boston, MA 02199

Dr. Duh is a pharmacoepidemiologist specializing in the safety, outcomes, economics, and utilizations of pharmaceuticals. She conducts and leads pharmacoepidemiology and pharmacovigilance studies for pharmaceutical companies to address drug safety issues raised by regulatory agencies, such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and provides strategic advice to address drug safety issues in the context of black box warnings, product withdrawals, limited access programs, and new drug applications (NDAs). Her extensive research has resulted in over 200 peer-reviewed publications in prominent journals, including one of the nine most-cited articles in *Current Medical Research and Opinion*, an article featured in an editorial in *COPD: Journal of Chronic Obstructive Pulmonary Disease*, and an article nominated for a 2009 Excellence Award by the *Journal of Managed Care Pharmacy*.

Through these investigations, Dr. Duh has collected and utilized data from clinical trials, medical record reviews, health insurance claims data, patient and physician surveys, and spontaneous report data. Dr. Duh has also been responsible for special tasks in assisting pharmaceutical, biotech, and medical device companies in preparation for FDA and Centers for Medicare & Medicaid Services (CMS) committee meetings, critical reviews of the planned study protocols, establishment of liaison with clinical communities, and CMS reimbursement analyses.

Dr. Duh has been appointed to several positions in academia and professional societies. She served as a chairperson of the Drug Safety and Epidemiology Board for the Drug Information Association (DIA), and was an adjunct assistant professor of pharmacoconomics and outcomes research at the Massachusetts College of Pharmacy and Allied Health Sciences. She is a visiting scholar in the Harvard School of Public Health's Department of Biostatistics and a guest lecturer in the Department of Epidemiology; she is featured on the Harvard Catalyst Profiles website. Dr. Duh was appointed to an expert panel convened by the Foundation for the National Institutes of Health's (FNIH's) Observational Medical Outcomes Partnership (OMOP) to develop methodologies for studying drug-induced liver injuries on a national scale. She is a journal peer reviewer for *Pharmacoepidemiology and Drug Safety*, *Pharmacoconomics*, the *American Journal of Hospital-System Pharmacy*, *CHEST*, *Critical Care*, *Therapeutics and Clinical Risk Management*, the *American Journal of Kidney Diseases*, *Managed Care Interface*, *The American Journal of Managed Care*, *Nephrology Dialysis Transplantation*, *Expert Review of Pharmacoconomics and Outcomes Research*, *CNS Neuroscience & Therapeutics*, *Pediatric Pulmonology*, and the *British Journal of Haematology*. Dr. Duh is an elected member of the American Society of Hematology (ASH), and a member of the International Society for Pharmacoepidemiology (ISPE), and the International Society for Pharmacoconomics and Outcomes Research (ISPOR).

Dr. Duh received an Sc.D. degree from the Harvard School of Public Health, with a concentration in pharmacoepidemiology and a minor in biostatistics and health policy and management. She received an M.P.H. degree in chronic disease epidemiology from Yale School of Medicine, and a B.S. degree in pharmacy from Kaohsiung Medical College in Taiwan.

EDUCATION

- 1996 Sc.D., pharmacoepidemiology, biostatistics, and health policy and management, Harvard School of Public Health
- 1992 M.P.H., chronic disease epidemiology and public health, Yale School of Medicine
- 1990 B.S., pharmacy, Kaohsiung Medical College, Taiwan

EMPLOYMENT

- 2001–Present Analysis Group, Inc.
Managing Principal (Partner) and Chief Epidemiologist (2009–Present)
Vice President (2003–2009)
Senior Associate (2001–2002)
- 1999–2001 Ingenix Pharmaceutical Services
Senior Associate Epidemiologist
- 1999 Astra Pharmaceuticals, L.P.
Pharmacoepidemiologist
- 1997–1999 AstraZeneca R&D
Pharmacoepidemiology Consultant
- 1996–1997 Astra USA, Inc.
Clinical Scientist/Project Manager
- 1996–1997 Drug Information Association
Epidemiology Session Chairperson
- 1992–1996 Harvard School of Public Health
Research Fellow in Pharmacoepidemiology Program

PROFESSIONAL AFFILIATIONS

Department of Biostatistics, Harvard University School of Public Health

Visiting Scholar (2012–Present)

Department of Epidemiology, Harvard University School of Public Health

Guest Lecturer (2007–2012, 2015)

Massachusetts College of Pharmacy and Allied Health Science

Adjunct Assistant Professor of Pharmacoepidemiology and Pharmacoeconomics (1996–1999)

American Society of Hematology (ASH)

Elected Member

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Member

International Society for Pharmacoepidemiology (ISPE)

Member

JOURNAL PEER REVIEWER

Various Peer-Reviewed Journals

American Journal of Hospital-System Pharmacy
American Journal of Kidney Diseases
The American Journal of Managed Care
The British Journal of Haematology
CHEST
CNS Neuroscience & Therapeutics
Critical Care

Expert Review of Pharmacoeconomics and Outcomes Research
Managed Care Interface
Nephrology Dialysis Transplantation
Pediatric Pulmonology
Pharmacoeconomics
Pharmacoepidemiology and Drug Safety
Therapeutics and Clinical Risk Management

JOURNAL PUBLICATIONS

1. Duh MS, Shepard MJ, Wilberger JE, Bracken MB. The effectiveness of surgery on the treatment of acute spinal cord injury and its relation to pharmacological treatment. *Neurosurgery*. 1994 08; 35(2): 240-248; discussion 248-249.
2. Duh MS, Walker Am, Ayanian JZ. Interpretation of the Weight Matrix in an Artificial Neural Network. *Am J Epidemiol*. 1998: 1112-1122.
3. Duh MS, Walker AM, Pagano M, Kronlund K. Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example. *Am J Epidemiol*. 1998 02; 147(4): 407-413.
4. Duh MS, Walker AM, Ayanian JZ. Epidemiologic interpretation of artificial neural networks. *Am J Epidemiol*. 1998 06; 147(12): 1112-1122.
5. Duh MS, Walker AM, Kronlund KH, Jr. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. *Pharmacoepidemiol Drug Saf*. 1999 07; 8(4): 275-283.
6. Duh MS, Walker AM, Lindmark B, Laties AM. Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. *Ann Allergy Asthma Immunol*. 2000 11; 85(5): 356-361.
7. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ. The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States. *Crit Care Med*. 2004 01; 32(1): 39-52.
8. Shorr AF, Duh MS, Kelly KM, Kollef MH. Red blood cell transfusion and ventilator-associated pneumonia: A potential link? *Crit Care Med*. 2004 03; 32(3): 666-674.
9. Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ. Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve. *Oncologist*. 2005 06; 10(6): 438-448.
10. Duh MS, L Mark T. Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia. *Expert Rev Pharmacoecon Outcomes Res*. 2005 08; 5(4): 383-394.
11. Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia. *Curr Med Res Opin*. 2005 10; 21(10): 1677-1682.

12. Campos SM, Duh MS, Lefebvre P, Rosberg J. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. *J Natl Compr Canc Netw*. 2005 11; 3(6): 807-816.
13. Gosselin A, McKenzie R, Lefebvre P, Mody S, Piech C, Duh M. Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer. *P AND T*. 2006 31(10): 594.
14. Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, Cole JA, Cook SF, Walker AM. Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. *Pharmacoepidemiol Drug Saf*. 2006 01; 15(1): 47-56.
15. Smith M, Boyce S, Moynour E, Duh MS, Raut M, Brandman J. Assessing the risk of clinical fracture in men with non-metastatic prostate cancer receiving gonadotropin-releasing hormone agonist therapy. *J Urol*. 2006 01; 175(1): 136-139.
16. Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, Thorn D, Person J, Duh MS. Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. *J Am Acad Dermatol*. 2006 03; 54(3): 448-457.
17. Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. *Dig Dis Sci*. 2006 05; 51(5): 877-884.
18. Mincey BA, Duh MS, Thomas SK, Moynour E, Marynchenko M, Boyce SP, Mallett D, Perez EA. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. *Clin Breast Cancer*. 2006 06; 7(2): 127-132.
19. Fowler JF, Duh MS, Chang J, Person J, Thorn D, Raut M, Ghosh A, Den E, Emani S. A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization. *Cutis*. 2006 06; 77(6): 385-392.
20. Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. *Clin Ther*. 2006 09; 28(9): 1443-1450.
21. Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. *Curr Med Res Opin*. 2006 09; 22(9): 1623-1631.
22. Duh MS, Latypova A, Greenberg P. Impact and treatment of anemia in the elderly: clinical, epidemiological and economic perspectives. *Expert Rev Pharmacoecon Outcomes Res*. 2006 10; 6(5): 577-590.
23. Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. *Drugs Aging*. 2006 12; 23(12): 969-976.
24. Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH. Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. *J Am Soc Nephrol*. 2006 12; 17(12): 3497-3502.
25. Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease. *Dis Manag*. 2007 02; 10(1): 37-45.
26. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. *Epilepsia*. 2007 03; 48(3): 464-469.

27. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antras L, Smith M, Neary MP, Duh MS. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. *Cancer*. 2007 03; 109(6): 1090-1096.
28. Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF. Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study. *Crit Care*. 2007 06; 11(3): R63.
29. Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. *Dis Manag*. 2007 08; 10(4): 216-225.
30. Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. *Am J Health Syst Pharm*. 2007 09; 64(18): 1943-1949.
31. Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G. The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective. *Manag Care Interface*. 2007 10; 20(10): 26-32.
32. Moyneur E BB, Mody SH, Fournier A, Mallet D, Duh MS. Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer's perspective. *J Health Prod*. 2007 10: 309.
33. Chen L, Antras L, Duh MS, Levy N, Neary M, O'Brien ME, von Pawel J. Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer. *Curr Med Res Opin*. 2007 11; 23(11): 2741-2752.
34. Duh M, Mody S, Laliberté F, McKenzie R, Bookhart B, Lefebvre P. Drug utilization and costs of erythropoietic-stimulating agents in chronic kidney disease patients not receiving dialysis. *Manag Care Interface*. 2007 12; 20 (12): 14-19.
35. Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen. *Ann Pharmacother*. 2008 01; 42(1): 16-23.
36. Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE. Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents. *Pharmacoeconomics*. 2008 01; 26(2): 99-120.
37. Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS. The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective. *Dis Manag*. 2008 02; 11(1): 49-58.
38. Duh MS, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT. Anaemia and the risk of injurious falls in a community-dwelling elderly population. *Drugs Aging*. 2008 04; 25(4): 325-334.
39. Duh MS, Reynolds Weiner J, Lefebvre P, Neary M, Skarin AT. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. *Curr Med Res Opin*. 2008 04; 24(4): 967-974.
40. Weiner JR, Toy EL, Sacco P, Duh MS. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. *Expert Opin Pharmacother*. 2008 04; 9(5): 751-766.
41. LeLorier J, Duh MS, Paradis PE, Latremouille-Viau D, Lefebvre P, Manjunath R, Sheehy O. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. *Curr Med Res Opin*. 2008 04; 24(4): 1069-1081.

42. LeLorier J, *Duh MS*, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. *Neurology*. 2008 05; 70(22 Pt 2): 2179-2186.
43. Moyo V, Lefebvre P, *Duh MS*, Yektashenas B, Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. *Ann Hematol*. 2008 07; 87(7): 527-536.
44. Fowler JF, *Duh MS*, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G. The impact of psoriasis on health care costs and patient work loss. *J Am Acad Dermatol*. 2008 11; 59(5): 772-780.
45. Faught E, *Duh MS*, Weiner JR, Guerin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. *Neurology*. 2008 11; 71(20): 1572-1578.
46. Laliberté F, Bookhart B, Corral M, Vekeman F, *Duh M*, Bailey R, Lefebvre P. Impact of anemia on hospitalization rates and costs in a diabetic and a hypertensive cohort of chronic kidney disease patients. *J Manage Care Med*. 2009 (12 (3)): 41-50.
47. Mundle S, Lefebvre P, Vekeman F, *Duh MS*, Rastogi R, Moyo V. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. *Cancer*. 2009 02; 115(4): 706-715.
48. Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, *Duh MS*, Tak Piech C, Lefebvre P. Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database. *J Med Econ*. 2009 03; 12(1): 1-8.
49. Faught RE, Weiner JR, Guerin A, Cunnington MC, *Duh MS*. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. *Epilepsia*. 2009 03; 50(3): 501-509.
50. Laliberte F, Bookhart BK, Vekeman F, Corral M, *Duh MS*, Bailey RA, Piech CT, Lefebvre P. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. *J Manag Care Pharm*. 2009 05; 15(4): 312-322.
51. Vekeman F, Bookhart BK, White J, McKenzie RS, *Duh MS*, Piech CT, Lefebvre P. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. *Transfusion (Paris)*. 2009 05; 49(5): 895-902.
52. Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, Wintfeld N, Neary M, *Duh MS*. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. *Support Care Cancer*. 2009 06; 17(6): 719-725.
53. *Duh MS*, Paradis PE, Latremouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J. The risks and costs of multiple-generic substitution of topiramate. *Neurology*. 2009 06; 72(24): 2122-2129.
54. Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, *Duh MS*. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. *Curr Med Res Opin*. 2009 07; 25(7): 1793-1805.
55. *Duh MS*, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. *Curr Med Res Opin*. 2009 08; 25(8): 2081-2090.

56. Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, *Duh MS*. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. *Cancer*. 2009 10; 115(20): 4839-4848.
57. *Duh MS*, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. *Expert Opin Pharmacother*. 2009 10; 10(14): 2317-2328.
58. *Duh MS*, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA. Impact of compliance with proton pump inhibitors on NSAID treatment. *Am J Manag Care*. 2009 10; 15(10): 681-688.
59. *Duh MS*, Fulcher NM, White LA, Jayawant SS, Ramamurthy P, Moynour E, Ong SH. Costs associated with cardiovascular events in patients with hypertension in US managed care settings. *J Am Soc Hypertens*. 2009 11; 3(6): 403-415.
60. Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, *Duh MS*. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. *J Cancer Res Ther*. 2010 01; 6(1): 31-35.
61. Raptis A, *Duh MS*, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. *Transfusion (Paris)*. 2010 01; 50(1): 190-199.
62. Signorovitch JE, Sheng *Duh M*, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. *Curr Med Res Opin*. 2010 02; 26(2): 355-363.
63. Michna E, *Duh MS*, Korves C, Dahl JL. Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. *Pain Med*. 2010 03; 11(3): 369-378.
64. Choueiri TK, *Duh MS*, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antras L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. *BJU Int*. 2010 05; 105(9): 1247-1254.
65. Labiner DM, Paradis PE, Manjunath R, *Duh MS*, Lafeuille MH, Latremouille-Viau D, Lefebvre P, Helmers SL. Generic antiepileptic drugs and associated medical resource utilization in the United States. *Neurology*. 2010 05; 74(20): 1566-1574.
66. Toy EL, Gallagher KF, Stanley EL, Swensen AR, *Duh MS*. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. *COPD*. 2010 06; 7(3): 214-228.
67. Helmers SL, Paradis PE, Manjunath R, *Duh MS*, Lafeuille MH, Latremouille-Viau D, Lefebvre P, Labiner DM. Economic burden associated with the use of generic antiepileptic drugs in the United States. *Epilepsy Behav*. 2010 08; 18(4): 437-444.
68. *Duh MS*, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE. Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications. *Pain Med*. 2010 11; 11(11): 1718-1725.
69. Scharre DW, Vekeman F, Lefebvre P, Mody-Patel N, Kahler KH, *Duh MS*. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study. *Drugs Aging*. 2010 11; 27(11): 903-913.

70. Mease PJ, Zimetbaum PJ, *Duh MS*, Vekeman F, Guerin A, Boerstoeel-Streefland M, Jiang W, Lefebvre P. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data (February). *Ann Pharmacother*. 2011 02: 179-188.
71. Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M, *Duh MS*. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. *BMC Cancer*. 2011 03; 11: 105.
72. Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, *Duh MS*. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. *Respir Med*. 2011 03; 105(3): 435-441.
73. Vekeman F, LaMori JC, Laliberte F, Nutescu E, *Duh MS*, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population. *J Med Econ*. 2011 04; 14(3): 324-334.
74. Helmers SL, *Duh MS*, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. *Epilepsy Behav*. 2011 10; 22(2): 370-375.
75. Lafeuille MH, *Duh MS*, Zhang J, Wertz D, Gu T, Swensen A, Lefebvre P. Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases. *J Asthma*. 2011 11; 48(9): 923-930.
76. Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antras L, Chen K, Sheng *Duh M*, Jayawant SS, Oh WK, Atkins MB, Choueiri TK. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. *Urol Oncol*. 2011 11; 29(6): 756-763.
77. Cella D, Pickard AS, *Duh MS*, Guerin A, Mishagina N, Antras L, Neary MP, McCann L, Hodge R, Sternberg CN. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. *Eur J Cancer*. 2012 02; 48(3): 311-323.
78. Vekeman F, LaMori JC, Laliberte F, Nutescu E, *Duh MS*, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P. In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty. *J Med Econ*. 2012 02; 15(4): 644-653.
79. Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, *Duh MS*. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease. *J Clin Pharm Ther*. 2012 04; 37(2): 173-181.
80. Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, *Duh MS*. Cost burden and treatment patterns associated with management of heavy menstrual bleeding. *J Womens Health (Larchmt)*. 2012 05; 21(5): 539-547.
81. Korves C, Eldar-Lissai A, McHale J, Lafeuille MH, Hwa Ong S, Sheng *Duh M*. Resource utilization and costs following hospitalization of patients with chronic heart failure in the US. *J Med Econ*. 2012 05; 15(5): 925-937.
82. Lefebvre P, Laliberte F, Nutescu EA, *Duh MS*, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. *J Manag Care Pharm*. 2012 06; 18(5): 363-374.
83. Lafeuille MH, Vekeman F, Wang ST, Kerrigan M, Menditto L, *Duh MS*. Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia. *Leuk Lymphoma*. 2012 06; 53(6): 1146-1154.

84. Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. *Medical Oncology*. 2012 06; 29(2): 786-794.
85. Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. *Ann Allergy Asthma Immunol*. 2012 07; 109(1): 59-64.
86. Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. *Adv Ther*. 2012 08; 29(8): 675-690.
87. Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. *Eur J Paediatr Neurol*. 2012 09; 16(5): 449-458.
88. Manjunath R, Paradis PE, Parise H, Lafeuille MH, Bowers B, Duh MS, Lefebvre P, Faught E. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. *Neurology*. 2012 10; 79(18): 1908-1916.
89. Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. *Urol Oncol*. 2012 11; 30(6): 848-855.
90. Johnson SJ, Sorg RA, Borker RD, Duh MS. Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed with Advanced Ovarian Cancer. *Clinical Ovarian and Other Gynecologic Cancer*. 2012 12; 5(2): 67-77. e1.
91. Garrison LP, Jr., Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. *Oncologist*. 2013 01; 18(1): 27-36.
92. Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. *Hypertension*. 2013 02; 61(2): 309-318.
93. Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. *Pediatr Blood Cancer*. 2013 05; 60(5): 828-835.
94. Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. *J Neurol Sci*. 2013 07; 330(1-2): 71-77.
95. Ivanova JI, Mytelka DS, Duh MS, Birnbaum HG, Cummings AK, San Roman AM, Price GL, Swindle RW. Evaluating the utility of existing patient-reported outcome scales in novel patient populations with pancreatic cancer, lung cancer, and myeloproliferative neoplasms using Medicare current beneficiary survey data. *Patient*. 2013 07; 6(3): 189-200.
96. Laliberte F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. *Patient*. 2013 07; 6(3): 213-224.

97. Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. *Cancer*. 2013 08; 119(16): 2990-2998.
98. Viridi NS, Lefebvre P, Parise H, Duh MS, Pilon D, Laliberte F, Sundaresan D, Garber L, Dirani R. Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naive adult patients with type 2 diabetes. *J Diabetes Sci Technol*. 2013 09; 7(5): 1229-1242.
99. Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. *BMC Psychiatry*. 2013 09; 13: 221.
100. Chu DS, Johnson SJ, Mallya UG, Davis MR, Sorg RA, Duh MS. Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. *J Ophthalmic Inflamm Infect*. 2013 11; 3(1): 64.
101. Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. *J Med Econ*. 2013 11; 16(11): 1290-1299.
102. Huynh L, McCoy M, Law A, Tran KN, Knuth S, Lefebvre P, Sullivan S, Duh MS. Systematic literature review of the costs of pregnancy in the US. *Pharmacoeconomics*. 2013 11; 31(11): 1005-1030.
103. Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S. All-cause and disease-related health care costs associated with recurrent venous thromboembolism. *Thromb Haemost*. 2013 12; 110(6): 1288-1297.
104. Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Karner P, Wong B. Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population. *Sarcoma*. 2013 12; 2013: 947413.
105. Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meininger G, Rupnow M. Opportunities for Improving Attainment of Quality Measures in Patients with Type 2 Diabetes Mellitus. *Am J Manag Care* 2014 01; 20(1).
106. Laliberte F, Lefebvre P, Law A, Duh MS, Pocoski J, Lynen R, Darney P. Medicaid spending on contraceptive coverage and pregnancy-related care. *Reprod Health* 2014 03; 11(1): 20.
107. Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, Markowitz M, Duh MS, Lefebvre P. Burden of schizophrenia on selected comorbidity costs. *Expert Rev Pharmacoecon Outcomes Res*. 2014 04; 14(2): 259-267.
108. Carlozzi NE, Victorson D, Sung V, Beaumont JL, Cheng W, Gorin B, Duh MS, Samuelson D, Tulskey D, Gutierrez S, Nowinski CJ, Mueller A, Shen V, Frank S. HD-PRO-TRIAD Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease. *Tremor Other Hyperkinet Mov. (N Y)* 2014 04; 4: 223.
109. Victorson D, Carlozzi NE, Frank S, Beaumont JL, Cheng W, Gorin B, Duh MS, Samuelson D, Tulskey D, Gutierrez S, Nowinski CJ, Mueller A, Shen V, Sung V. Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives. *Tremor Other Hyperkinet Mov. (N Y)* 2014 04; 4: 224.
110. Oglesby A, Korves C, Laliberte F, Dennis G, Rao S, Suthoff ED, Wei R, Duh MS. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. *Appl Health Econ Health Policy* 2014 04; 12(2): 179-190.

111. Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. *Curr Med Res Opin.* 2014 08; 30(8): 1643-1655.
112. Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. *Oncologist* 2014 09; 19(9): 930-936.
113. Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. *Clin Lymphoma Myeloma Leuk.* 2014 10; 14(5): 380-388.
114. Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M. Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States. *Hum Vaccin Immunother.* 2014 11; 10(8): 2255-2266.
115. Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS. Is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database. *J Card Fail.* 2014 11; 20(11): 853-863.
116. Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS. Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population. *Melanoma Res.* 2014 12; 24(6): 602-610.
117. Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. *Cancer Med.* 2014 12; 3(6): 1517-1526.
118. Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS. Pulse pressure and stroke risk: development and validation of a new stroke risk model. *Curr Med Res Opin.* 2014 12; 30(12): 2453-2460.
119. Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA. Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs. *J Med Econ.* 2015 01; 18(12): 1060-1070.
120. Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control. *J Med Econ.* 2015 02; 18(2): 113-125.
121. Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS. The epidemiology of herpes zoster and its complications in Medicare cancer patients. *BMC Infect Dis.* 2015 02; 15: 106.
122. Lafeuille MH, Grittner AM, Fortier J, Muser E, Fasteneau J, Duh MS, Lefebvre P. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. *Am J Health Syst Pharm.* 2015 03; 72(5): 378-389.
123. Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM. Incremental direct and indirect costs of untreated vasomotor symptoms. *Menopause.* 2015 03; 22(3): 260-266.

124. Jordan L, Adams-Graves P, Kanter-Washko J, Oneal PA, Sasane M, Vekeman F, Bieri C, Magestro M, Marcellari A, *Duh MS*. Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy. *Curr Med Res Opin*. 2015 03; 31(3): 513-523.
125. Wagner MJ, Amodu LI, *Duh MS*, Korves C, Solleza F, Manson SC, Diaz J, Neary MP, Demetri GD. A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments. *BMC Cancer*. 2015 03; 15(175): 175.
126. Yermakov S, Davis M, Calnan M, Fay M, Cox-Buckley B, Sarda S, *Duh MS*, Iyer R. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. *J Med Econ*. 2015 06; 18(9): 711-720.
127. Toy EL, Vekeman F, Lewis MC, Oglesby AK, *Duh MS*. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. *Curr Med Res Opin*. 2015 08; 31(8): 1561-1572.
128. Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, *Duh MS*, Sacco P. Patient and Caregiver Burden Associated with Fragile X Syndrome in the United States. *Am J Intellect Dev Disabil*. 2015 09; 120(5): 444-459.
129. Blinder MA, *Duh MS*, Sasane M, Trahey A, Paley C, Vekeman F. Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease. *J Emerg Med*. 2015 10; 49(4): 513-522.e1.
130. Vekeman F, Cheng WY, Sasane M, Huynh L, *Duh MS*, Paley C, Mesa RA. Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy. *Leuk Lymphoma*. 2015 10; 56(10): 2803-2811.
131. Kruse G, Wong BJ, *Duh MS*, Lefebvre P, Lafeuille MH, Fastenau JM. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment. *Pharmacoeconomics*. 2015 10; 33(10): 1049-1067.
132. Xiao Y, Muser E, Lafeuille MH, Pesa J, Fastenau J, *Duh MS*, Lefebvre P. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. *J Comp Eff Res*. 2015 11; 4(6): 579-592.
133. Lefebvre P, *Duh MS*, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. *J Allergy Clin Immunol*. 2015 12; 136(6): 1488-1495.
134. Krishnarajah G, *Duh MS*, Korves C, Demissie K. Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States. *PLoS One*. 2016 01; 11(1): e0145977.
135. Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, *Duh MS*, Lefebvre P. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics. *Curr Med Res Opin*. 2016 02; 32(4): 759-769.
136. Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, *Duh MS*, Paley C, Adams-Graves P. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. *J Med Econ*. 2016 03; 19(3): 292-303.
137. Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, *Duh MS*. Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database. *Pharmacoepidemiol Drug Saf*. 2016 04; 25(4): 413-421.

138. Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. *Leukemia*. 2016 04; 30(4): 995-998.
139. Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S. Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance. *Hum Vaccin Immunother*. 2016 05; 12(5): 1235-1243.
140. Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS. Real-world glyceemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study. *Curr Med Res Opin*. 2016 06; 32(6): 1151-1159.
141. Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. *Menopause*. 2016 06; 23(6): 600-610.
142. Dalal AA, Duh MS, Gozalo L, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Lefebvre P. Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma. *J Manag Care Spec Pharm*. 2016 07; 22(7): 833-847.
143. Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Vekeman F, Gauthier-Loiselle M, Duh MS, Merrigan JF, Schatz M. Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data. *Ann Am Thorac Soc*. 2016 07; 13(7): 1067-1075.
144. Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS. Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population. *Reprod Health*. 2016 08; 13(1): 96.
145. DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. *J Manag Care Spec Pharm*. 2016 10; 22(10): 1204-1214.
146. Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa J, Clancy Z, Fastenau J, Durkin M. Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia. *Am Health Drug Benefits*. 2016 10; 9(7): 399-410.
147. Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B. Impact of Paliperidone Palmitate versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia. *J Clin Psychiatry*. 2016 10; 77(10): e1332-e1341.
148. Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, Fortier J, Emond B, Duh MS, Dezube BJ. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed with Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records from US Community Oncology Practices. *Clin Lymphoma Myeloma Leuk*. 2016 11; 16(11): 625-636 e3.
149. Duh MS, Cremieux P, Audenrode MV, Vekeman F, Karner P, Zhang H, Greenberg P. Can social media data lead to earlier detection of drug-related adverse events? *Pharmacoepidemiol Drug Saf*. 2016 12; 25(12): 1425-1433.
150. Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA. Burden of systemic glucocorticoid-related complications in severe asthma. *Curr Med Res Opin*. 2017 01; 33(1): 57-65.

151. Kageleiry A, Samuelson D, *Duh MS*, Lefebvre P, Campbell J, Skotko BG. Out-of-pocket medical costs and third-party healthcare costs for children with Down syndrome. *Am J Med Genet A*. 2017 03; 173(3): 627-637.
152. Cheng WY, *Duh MS*, Xiao Y, Coe A, Hao Y, Vekeman F, Bobbili PJ, Blinder M. Disease-stratified adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets. *Value Health*. 2017 05; 20 (5): A232.
153. Herring M, Huynh L, *Duh MS*, Vekeman F, Tiew A, Neary M, Bergsland E. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. *Med Oncol*. 2017 05; 34(5): 88.
154. Balcom WB, Mishol DN, Eapen S, Bookhart BK, Nutescu EA, Schein JR, *Duh MS*. A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery. *Curr Orthop Pract*. 2017 05; 23(3): 221-228.
155. DerSarkissian M, Bhak RH, Huang J, Buchs S, Vekeman F, Smolarz BG, Brett J, Ganguly R, *Duh MS*. Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population. *Curr Med Res Opin*. 2017 06; 33(6): 1105-1110.
156. Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, *Duh MS*. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. *BMC Endocr Disord*. 2017 06; 17(1): 32.
157. Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, *Duh MS*. Real-world Characteristics and Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy versus Androgen Receptor-targeted Therapy after Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. *Clin Genitourin Cancer*. 2017 06: 50-57.
158. Mapel D, Laliberte F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, *Duh MS*, Patel J. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. *Int J Chron Obstruct Pulmon Dis*. 2017 06; 12: 1825-1836.
159. Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, *Duh MS*, Shiner B, Young-Xu Y. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse. *Clin Ther*. 2017 07; 39(7): 1380-1395.
160. Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, *Duh MS*, Shen V, Saurer TB, Isojarvi J. Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome. *Epilepsy Behav*. 2017 08; 73: 46-50.
161. Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, *Duh MS*, McGarry LJ, Kantarjian HM, Cortes JE. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. *Cancer*. 2017 08; 123(15): 2875-2880.
162. Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, *Duh MS*. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. *Med Oncol*. 2017 08; 34(9): 160.

163. Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, *Duh MS*, van de Velde H, Niculescu L, Bonthapally V, Goy A. Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices. *Leuk Lymphoma*. 2017 08; 58(8): 1968-1972.
164. Huynh L, Totev T, Vekeman F, Neary MP, *Duh MS*, Benson AB. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. *J Med Econ*. 2017 09; 20(9): 945-951.
165. McKay R, Haider B, *Duh MS*, Valderrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen L, Kantoff P. Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases. *Prostate Cancer Prostatic Dis*. 2017 09; 20(3): 276-282.
166. Krishnarajah G, Kageleiry A, Korves C, Lefebvre P, *Duh MS*. Public health impact of Rotarix vaccination among commercially insured children in the United States. *Vaccine*. 2017 09; 35(37): 5065-5072.
167. Faught E, Laliberte F, Wang Z, Barghout V, Haider B, Lejeune D, Germain G, Choi J, Wagh A, *Duh MS*. Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States. *Epilepsia*. 2017 10; 58(10): 1742-1748.
168. Ivanova JI, Saverno KR, Sung J, *Duh MS*, Zhao C, Cai S, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. *Med Oncol*. 2017 11; 34(12): 193.
169. Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan JFP, *Duh MS*. Claims-based risk model for first severe COPD exacerbation. *Am J Manag Care*. 2018 02; 24(2): e45-e53.
170. Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, *Duh MS*. Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. *Clin Genitourin Cancer*. 2018 02; 16(1): 50-57.
171. Ruud Bosch JLH, Vekeman F, *Duh MS*, Neary M, Magestro M, Fortier J, Karner P, Ionescu-Ittu R, Zonnenberg BA. Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center. *Int Urol Nephrol*. 2018 03; 50(3): 459-467.
172. Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, Roy A, *Duh MS*. Value of transfusion independence in severe aplastic anemia from patients' perspectives – a discrete choice experiment. *Journal of Patient-Reported Outcomes*. 2018 03; 2(1): 13.
173. Jabbour E, DerSarkissian M, *Duh MS*, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM. Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. *Clin Lymphoma Myeloma Leuk*. 2018 04; 18(4): 257-265.
174. Tanton D, *Duh MS*, Lafeuille MH, Lefebvre P, Pilon D, Zhdanova M, Emond B, Inman D, Bailey RA. Real-world evaluation of HbA1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida. *Curr Med Res Opin*. 2018 06; 34(6): 1099-1115.

175. Walker AM, Schneeweiss S, DerSarkissian M, *Duh MS*. Removal of ineligible outcome cases reduces confounding. *Clin Epidemiol*. 2018 06; 10: 575-579.
176. Slater J, Chung S, Huynh L, *Duh MS*, Gorin B, McMicken C, Ziemann A, Isojarvi J. Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials. *Epilepsy Res*. 2018 07; 143: 120-129.
177. Yan S, DerSarkissian M, Bhak RH, Lefebvre P, *Duh MS*, Krishnarajah G. Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. *Curr Med Res Opin*. 2018 07; 34(7): 1261-1269.
178. Ortega H, Llanos JP, Lafeuille MH, Germain G, *Duh MS*, Bell CF, Sama SR, Hahn B. Burden of disease associated with a COPD eosinophilic phenotype. *Int J Chron Obstruct Pulmon Dis*. 2018 08; 13: 2425-2433.
179. Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, *Duh MS*, Bookhart B, Wysham CH. Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. *Cardiovasc Diabetol*. 2018 08; 17(1): 118.
180. Ortega H, Llanos JP, Lafeuille MH, *Duh MS*, Germain G, Lejeune D, Sama S, Bell C, Hahn B. Effects of Systemic Corticosteroids on Blood Eosinophil Counts in Asthma: Real-World Data. *J Asthma*. 2018 08: 1-26.
181. Vekeman F, Weiss L, Aram J, Ionescu-Ittu R, Moosavi S, Xiao Y, Cheng WY, Bhak RH, Tawadrous M, Capparella MR, Montravers P, *Duh MS*. Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication. *BMC Infect Dis*. 2018 08; 18(1): 438.
182. Llanos JP, Ortega H, Germain G, *Duh MS*, Lafeuille MH, Tiggelaar S, Bell CF, Hahn B. Health characteristics of patients with asthma, COPD and asthma-COPD overlap in the NHANES database. *Int J Chron Obstruct Pulmon Dis*. 2018 09; 13: 2859-2868.
183. Kallenbach L, Shui AM, Cheng WY, Fan T, Hu W, Zichlin ML, *Duh MS*, Ye F, Levin PA. Predictors and clinical outcomes of treatment intensification in patients with type 2 diabetes uncontrolled on basal insulin in a real-world setting. *Endocr Pract*. 2018 09; 24(9): 805-814.
184. Patel AK, *Duh MS*, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS. Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib. *Clin Colorectal Cancer*. 2018 09; 17(3): e531-e539.
185. Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, *Duh MS*, Nandal S, Blinder M. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets. *Curr Med Res Opin*. 2018 11; 34(11): 1959-1966.
186. Khelif A, Saleh MN, Salama A, Portella M, *Duh MS*, Ivanova J, Grotzinger K, Roy AN, Bussel JB. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. *Am J Hematol*. 2018 11: 200-208.
187. Laliberte F, Dea K, *Duh MS*, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. *Menopause*. 2018 11; 25(11): 1297-1305.
188. Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, *Duh MS*, Neary MP, Cella D. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. *Medicine (Baltimore)*. 2018 11; 97(47): e13390.

189. Zonnenberg BA, Neary MP, Duh MS, Ionescu-Ittu R, Fortier J, Vekeman F. Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus. *PLoS One*. 2018 11; 13(11): e0204646.
190. Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. *Urol Oncol*. 2018 11; 36(11): 500 e501-500 e9.
191. Ghate SR, Ionescu-Ittu R, Burne R, Ndife B, Laliberte F, Nakasato A, Duh MS. Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy. *Curr Med Res Opin*. 2018 12; 34(12): 2169-2176.
192. Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberte F, Nakasato A, Burne R, Duh MS. Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. *Melanoma Res*. 2018 12; 28(6): 618-628.
193. Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. *Oncologist*. 2019 01; 24(8): 1056-1065.
194. Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. *Oncologist*. 2019 01; 24(8): 1066-1075.
195. Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R. Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. *Clin Ther*. 2019 3; 41(3): 477-493 e7.
196. Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB. Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis. *Am J Hematol*. 2019 04. 94(4):E96-E99.
197. Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. *J Diabetes Complications*. 2019 02; 33(2): 140-147.
198. Tarhini A, Ghate S, Ionescu-Ittu R, Shi S, Nakasato A, Ndife B, Laliberte F, Burne R, Duh MS. Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study. *Future Oncol*. 2019 02; 15(4): 359-370.
199. Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. *BMC Cancer*. 2019 03; 19(1): 274.
200. Vekeman F, Pina-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Sheng Duh M, Shen V, Saurer TB, Montouris GD, Isojarvi J. Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology. *Curr Med Res Opin*. 2019 03: 1-6.

201. Appukkuttan S, Yaldo A, Gharibo M, Babajanyan S, Duchesneau E, Zichlin ML, Bhak RH, *Duh MS*. A budget impact analysis of the introduction of copanlisib for treatment of relapsed follicular lymphoma in the United States. *J Manag Care Spec Pharm*. 2019 04; 25(4): 437-446b.
202. Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberte F, Nakasato A, *Duh MS*. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive. *Melanoma Res*. 2019 06; 29(3): 301-310.
203. Ghaswalla PK, Patterson BJ, Cheng WY, Duchesneau E, Machecha M, *Duh MS*, Trofa AF. The role of provider characteristics on the hepatitis A and B vaccination status of adults in the United States during 2007-2015. *Prev Med Rep*. 2019 02; 14: 100833.
204. Cheng WY, Chang R, Novy P, O'Connor C, *Duh MS*, Hogeia CS. Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations. *Hum Vaccin Immunother*. 2020; 16(1) 176-188.
205. Ramasamy A, Laliberte F, Aktavoukian SA, Lejeune D, DerSarkissian M, Cavanaugh C, Smolarz BG, Ganguly R, *Duh MS*. Direct and Indirect Cost of Obesity Among the Privately Insured in the United States: A Focus on the Impact by Type of Industry. *J Occup Environ Med*. 2019 08; 61(11): 877-886.
206. Cortes J, Huynh L, Mendelson E, Brandt P, Dalal D, DerSarkissian M, Cortina D, Narkhede S, Sheng *Duh M*. Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study. *Leuk Lymphoma*. 2020 01; 61(1): 98-107.
207. Huynh L, Cai B, Cheng M, Lax A, Lejeune D, *Duh MS*, Kim MK. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors. *Pancreas*. 2019 10; 48(9): 1126-1135.
208. Averell CM, Laliberte F, *Duh MS*, Wu JW, Germain G, Faison S. Characterizing Real-World Use Of Tiotropium In Asthma In The USA. *J Asthma Allergy*. 2019 10; 12: 309-321.
209. Ramasamy A, Laliberte F, Aktavoukian SA, Lejeune D, DerSarkissian M, Cavanaugh C, Smolarz BG, Ganguly R, *Duh MS*. Direct, Absenteeism, and Disability Cost Burden of Obesity Among Privately Insured Employees: A Comparison of Healthcare Industry Versus Other Major Industries in the United States. *J Occup Environ Med*. 2019 10; 62(2): 98-107.
210. Averell CM, Stanford RH, Laliberte F, Wu JW, Germain G, *Duh MS*. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. *J Asthma*. 2019 10: 1-10.
211. Bobbili P, Ryan K, *Duh MS*, Dua A, Fernandes AW, Pavilack M, Gomez JE. Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer. *Future Oncol*. 2019 10; 15(29): 3381-3393.
212. Colao A, Grasso LFS, Di Cera M, Thompson-Leduc P, Cheng WY, Cheung HC, *Duh MS*, Neary MP, Pedroncelli AM, Maamari R, Pivonello R. Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study. *J Endocrinol Invest*. 2019 11; 43: 529-538.
213. Grivas P, DerSarkissian M, Shenolikar R, Laliberte F, Doleh Y, *Duh MS*. Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA. *Future Oncol*. 2019 11; 15(33): 3809-3818.

214. Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, *Duh MS*, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. *Eur Urol Oncol*. 2019 11; 27:S2588-9311(19)30160-9.
215. Vergeer M, de Ranitz-Greven WL, Neary MP, Ionescu-Ittu R, Emond B, Sheng *Duh M*, Jansen F, Zonnenberg BA. Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex. *Epilepsia Open*. 2019 12; 4(4): 581-592.
216. Bogart M, Stanford RH, Laliberte F, Germain G, Wu JW, *Duh MS*. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. *Int J Chron Obstruct Pulmon Dis*. 2019 12; 14: 343-352.
217. Subramanian J, Fernandes AW, Laliberté F, Pavilack M, DerSarkissian M, *Duh MS*. The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors. *Lung Cancer*. 2019 12; 138: 131-138.
218. Patel AK, Barghout V, Yenikomshian MA, Germain G, Jacques P, Laliberte F, *Duh MS*. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib. *Oncologist*. 2020 01; 25(1): e75-e84.
219. Savard M-F, Wells JC, Graham J, Dudani S, Steinharter JA, McGregor BA, Donskov F, Bjarnason GA, Vaishampayan UN, Hansen AR, Iafolla MAJ, Zanotti G, Huynh L, Chang R, *Duh MS*, Heng DYC. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. *The Oncologist*. 2020 01; 25(5): 422-430.
220. Shah BR, DerSarkissian M, Tsintzos SI, Xiao Y, May D, Lu X, Kinrich D, Davis E, Lefebvre P, *Duh MS*, Dasta JF. Adherence to heart failure management medications following cardiac resynchronization therapy. *Curr Med Res Opin*. 2020 02; 36(2): 199-207.
221. Wysham CH, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, *Duh MS*, Young JB. Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study. *Curr Med Res Opin*. 2020 02; 36(2): 219-227.
222. Bobbili P, Ryan K, DerSarkissian M, Dua A, Yee C, *Duh MS*, Gomez JE. Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer. *PLoS One*. 2020 03; 15(3): e0230444.
223. Peffault de Latour R, Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, *Duh MS*. Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study. *Ann Hematol*. 2020 04; 99(4): 743-752.
224. Chiang AC, Fernandes AW, Pavilack M, Wu JW, Laliberte F, *Duh MS*, Chehab N, Subramanian J. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. *BMC Cancer*. 2020 04; 20(1): 356.
225. Siffel C, DerSarkissian M, Kponee-Shovein K, Spalding W, Gu YM, Cheng M, *Duh MS*. Suicidal ideation and attempts in the United States of America among stimulant-treated, non-stimulant-treated, and untreated patients with a diagnosis of attention-deficit/hyperactivity disorder. *J Affect Disord*. 2020 04; 266: 109-119.

226. Bobbili P, Olufade T, DerSarkissian M, Shenolikar R, Yu H, *Duh MS*, Tung N. Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study. *Hered Cancer Clin Pract.* 2020 06; 18: 13.
227. Eichenfield LF, DiBonaventura M, Xenakis J, Lafeuille MH, *Duh MS*, Fakih I, Levenberg M, Cappelleri JC, Sikirica V. Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database. *Dermatol Ther (Heidelb).* 2020 06; 10: 791-806.
228. DerSarkissian M, Bhak RH, Oglesby A, Priest J, Gao E, Machecca M, Sharperson C, *Duh MS*. Retrospective analysis of comorbidities and treatment burden among patients with HIV infection in a US Medicaid population. *Curr Med Res Opin.* 2020 06: 1-8.
229. Morse MA, Liu E, Joish VN, Huynh L, Cheng M, Sheng *Duh M*, Seth K, Lapuerta P, Metz DC. Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study. *Cancer Manag Res.* 2020 07; 2020:12: 6607-6614.
230. Wells JC, Dudani S, Gan CL, Stukalin I, Azad A, Liow E, Donskov F, Yuasa T, Pal S, De Velasco G, Wood L, Hansen A, Beuselinck B, Kollmannsberger C, Powles T, McGregor B, *Duh MS*, Huynh L, Heng DYC. Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma. *European Urology Open Science* 2020 07; 19: e1105-e1106.
231. McKay RR, Silver R, Bhak RH, Korves C, Cheng M, Appukkuttan S, Simmons SJ, *Duh MS*, Taplin ME. Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. *Prostate Cancer Prostatic Dis* 2020 08.
232. Yu KH, Hendifar A, Alese O, Draper A, Abdelrahim M, Burns E, Khan G, Cockrum P, Bhak R, Nguyen C, DerSarkissian M, *Duh MS*, Bahary N. Real-world treatment patterns and effectiveness of liposomal irinotecan in a NAPOLI1-based regimen among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): A multi-academic center chart review. *Ann Oncol.* 2020 09; 31: S950-S951.
233. Metz DC, Liu E, Joish VN, Huynh L, Totev T, *Duh MS*, Seth K, Giacalone S, Lapuerta P, Morse MA. Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome. *Cancer Manag Res.* 2020 10; 12: 9713-9719.
234. LeWinter M, Kontzias A, Lin D, Cella D, DerSarkissian M, Zhou M, *Duh MS*, Lim-Watson M, Magestro M. Burden of Recurrent Pericarditis on Health-Related Quality of Life. *Am J Cardiol.* 2020 11, S0002-9149(20)31244-3.
235. Chung ES, Rickard J, Lu X, DerSarkissian M, Zichlin ML, Cheung HC, Swartz N, Greatsinger A, *Duh MS*. Real-World Economic Burden Among Patients With And Without Heart Failure Worsening After Cardiac Resynchronization Therapy. *Adv Ther.* 2020 11.
236. Wells JC, Graham J, Beuselinck B, Bjarnason GA, Donskov F, Hansen AR, McKay RR, Vaishampayan U, De Velasco G, *Duh MS*, Huynh L, Nguyen C, Zanotti G, Ramaswamy K, Choueiri TK, Heng DYC. Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer.* 2020 12; 18(4): e350-e359.
237. Gounder MM, Merriam P, Ratan R, Patel SR, Chugh R, Villalobos VM, Thornton M, Van Tine BA, Abdelhamid AH, Whalen J, Yang J, Rajarethinam A, *Duh MS*, Bobbili PJ, Huynh L, Totev TI, Lax AK, Agarwal S, Demetri GD. Real-World Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma. *Cancer* 2020 12.

238. Laliberté F, Raut M, Yang X, Germain G, Nahar A, Desai KD, MacKnight SD, Sen SS, Duh MS. Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA. *Target Oncol.* 2021 1; 16(1):85-94.

LAW PUBLICATIONS

1. “The Role of Epidemiology in Drug Safety Litigations,” with Paul E. Greenberg and Jennifer Weiner, *Food & Drug Law Institute Update*, Nov.–Dec. 2007, 31–34.
2. “Drug Safety and Risk Management Practice,” with Paul E. Greenberg and Lucia Antras, *Food & Drug Law Institute Update*, May–June, 2008, 35–38.
3. “What Attorneys Should Know About FDA’s MedWatch Data,” with Pierre Y. Cremieux, Paul E. Greenberg, and Brian Ellman, *Law360*, January 29, 2014.
4. “Learning From Social Media For Adverse Event Reporting,” with Brian Ellman, Marc Van Audenrode, Paul Greenberg, and Pierre Cremieux., *Law360*, May 23, 2017.

HONORS

- 1992–1996 Harvard University: Pharmacoepidemiology Teaching and Training Award
- 1994 Harvard University: Teaching Fellow (honorary award)
- 1992 Yale University: National Collaborative Spinal Cord Study Training Award
- 1992 Yale University: Scholarship Award for Distinctive Doctoral Applicant

INVITED SPEECHES

“Application of pharmacoepidemiology to drug safety litigation,” Pharmacoepidemiology Seminar Series, Harvard School of Public Health, Boston (2003)

“A new dimension of disease burden: Absenteeism and presenteeism,” Health Economics and Outcomes Research Seminar Series, Harvard School of Public Health, Boston (2006)

“Courtroom pharmacoepidemiology: Application of pharmacoepidemiology to drug safety litigation,” Department of Epidemiology Seminar Series, Harvard School of Public Health, Boston (2009)

“Applications of Epidemiology to Risk Evaluation and Mitigation Strategies (REMS) and Drug Safety Litigation,” Seminars on Drug Safety and Comparative Effectiveness, Harvard School of Public Health, Boston (2011)

“Pharmacovigilance and pharmacoepidemiology in pharmaceutical litigation,” lunch seminar presented to Covington & Burling LLP, Washington, DC (2014)

“Pharmacovigilance and social media data,” Department of Epidemiology Seminar Series, Harvard T.H. Chan School of Public Health, Boston (2015)

“The Role of Biostatistician and Epidemiologist in Mitigating Risk of Share Price Decline,” lunch seminar presented to Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. (2017)

“Risks and Rewards of Accelerated FDA Pathways,” panelist, seminar sponsored by Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C., Boston (2018)

“Lightning Talk,” Department of Biostatistics Series, Harvard School of Public Health, Boston (2019)